Sequence Liability Identification
As a leading solution provider who is focused on therapeutic antibody discovery and development, Creative Biolabs has established a powerful antibody engineering platform including reformatting and production, epitope binning and mapping, antibody humanization platform, antidboy maturation, measurement, sequence liability identification, immunogenicity prediction, therapeutic developability analysis and other antibody specialization and modification services.
Sequence Liability Identification Service
Post-translational modifications (PTMs) of antibody have the potential to affect affinity, stability, potency and homogeneity of an antibody, and this will result in complicated process in downstream development. The bioactivity and production of various isoforms of the product will be impacted. PTMs normally include deamidation, isomerization, oxidation, glycosylation, free thiol, pyro-Glutamate, C-terminal Lysine etc.
To identify the sequences within antibody variable regions, Creative Biolabs has developed algorithms to offer this kind of service to improve the potential product quality. We are dedicated to helping our clients to make smarter decisions about eliminating the program earlier in the antibody engineering process or selecting the liability free antibodies for further development. We aim to provide critical insight into your project and reduce your cost via foreseeing potential quality risks.
Scope
|
We provide sequence liability identification service for variable heavy and variable light chains.
The following PTMFs can be analyzed including, but not limited to, N-linked glycosylation, deamidation, isomerization, oxidation, pyro-glutamate formation, and c-terminal lysine.
|
Material needed
|
Before performing sequence liability identification service, please deliver amino acid sequence of finalized heavy and light chain variable regions.
|
Deliverables
|
Final report with potential sequence liabilities will be analyzed and sent to you.
|
We also provide relevant antibody sequencing services:
-
Antibody variable region sequencing and cloning;
-
N-terminal protein sequencing service;
-
De novo antibody sequencing.
With extensive experience in providing antibody engineering solutions, Creative Biolabs is committed to excellence in sequence liability identification service and others. We aim to help you get the high-quality antibody for therapeutic product development, and make smart decisions to go or not to go. For more detailed information, please feel free to contact us at your convenience.
For Research Use Only | Not For Clinical Use